As sponsors and CROs increasingly seek experienced Phase I sites with diverse patient populations, FOMAT’s new capabilities position the organization as a premier destination for early-phase drug development in California. The launch represents years of infrastructure investment and operational preparation, resulting in a facility and team ready to support the most demanding early phase protocols.
Phase I Clinical Trials California: State of the Art Facilities in Oxnard
Comprehensive Early Phase Capabilities
FOMAT’s Phase I clinical trials California unit offers a full range of early phase services, including pharmacokinetic and pharmacodynamic studies as well as first in human trials. The facility is equipped for both simple and complex trials across multiple therapeutic areas including Infectious Diseases, Neurology, Endocrinology, and Cardiology. This breadth of capability ensures that sponsors and CROs can bring a wide variety of early phase protocols to a single, experienced site.
The Phase I unit is vendor qualified by leading CROs and sponsors, providing industry partners with the assurance of quality and compliance required for early phase research. This qualification reflects FOMAT’s investment in infrastructure, staffing, and processes specifically designed to meet the rigorous standards of Phase I trial execution.
Specialized Staff and Patient Centered Operations
FOMAT’s Phase I team combines clinical expertise with a deep understanding of the operational demands of early phase research. From protocol feasibility through study completion, the team is equipped to support sponsors and CROs at every stage of the trial lifecycle. The Oxnard location provides convenient access to a large and diverse patient population, a key advantage for sponsors seeking representative enrollment for first in human and early phase studies.
“Our new Phase I unit represents a significant step forward in our mission to provide top notch clinical services and improve diversity in clinical trials,” said Nicholas Focil, CEO of FOMAT. “By bringing early phase trials to underrepresented communities, we are fostering a more inclusive approach to drug development.”
Commitment to Diversity in Phase I Clinical Trials California
Reaching Underrepresented Communities
A core mission driving FOMAT’s Phase I clinical trials California launch is improving patient diversity in early phase research. By locating the unit in Oxnard and leveraging FOMAT’s existing community relationships across Ventura County, the organization ensures that underrepresented populations have access to cutting edge treatments and therapies from the earliest phases of development.
This approach not only fosters inclusion but also contributes to more comprehensive and representative research outcomes. Sponsors and CROs benefit from access to a patient population that reflects the diversity increasingly required by FDA guidance, while patients in underserved communities gain access to innovative therapies that might not otherwise be available locally.
A Strategic Asset for Sponsors and CROs
For industry partners evaluating Phase I sites in California, FOMAT offers a unique combination of vendor qualified facilities, diverse patient access, experienced staff, and a proven track record across Phase I through IV research. The integration of Phase I capabilities into FOMAT’s existing site network creates efficiencies for sponsors looking to advance compounds from early phase through later stage development within a single trusted partner.
About FOMAT
As California’s largest research site network, FOMAT partners with sponsors and CROs to advance clinical research and improve patient outcomes. With a strong commitment to diversity, FOMAT continues to drive healthcare innovation across multiple therapeutic areas. Learn more about FOMAT’s site network here.
Learn more about FDA guidance on early-phase clinical research at the FDA Clinical Research website.